Table 2 Demographic data of patients with MCD according to age of onset.

From: Demographics and treatment of patients with primary nephrotic syndrome in Japan using a national registry of clinical personal records

N

 ≤ 19 y/o

20–39 y/o

40–64 y/o

65–74 y/o

 ≥ 75 y/o

P-value

1038

1042

895

212

118

Age of onset (yrs)

11 (5, 16)

29 (24, 34)

50 (44, 57)

68 (67, 71)

79 (76, 82)

 < 0.001a,b,c,d,e,f,g,h,i

Age at renal biopsy (yrs)*

17 (14, 19)

31 (25, 36)

51 (45, 58)

69 (67, 72)

79 (77, 83)

 < 0.001a,b,c,d,e,f,g,h,i

Age of enrollment (yrs)

24 (20, 32)

38 (32, 44)

56 (49, 63)

71 (68, 74)

81 (78, 84)

 < 0.001a,b,c,d,e,f,g,h,i

Male, n (%)

703 (67.7%)

551 (52.9%)

447 (49.9%)

131 (61.8%)

67 (56.8%)

 < 0.001a,b,h

Present treatment

 Oral PSL

862 (83.0%)

927 (89.0%)

796 (88.9%)

187 (88.2%)

109 (92.4%)

 < 0.001a,b,d

 IV mPSL

57 (5.5%)

81 (7.8%)

79 (8.8%)

26 (12.3%)

13 (11.0%)

0.002c

 Cyclosporine

539 (51.9%)

527 (50.6%)

376 (42.0%)

76 (35.8%)

41 (34.7%)

 < 0.001b,c,d,e,f,g

 Mizoribine

178 (17.1%)

106 (10.2%)

98 (10.9%)

15 (7.1%)

6 (5.1%)

 < 0.001a,b,c,d

 MMF

79 (7.6%)

7 (0.7%)

0 (0.0%)

0 (0.0%)

0 (0.0%)

 < 0.001a,b,c,d

 Rituximab

120 (11.6%)

48 (4.6%)

29 (3.2%)

2 (0.9%)

0 (0.0%)

 < 0.001a,b,c,d

 PSL + cyclosporine

471 (45.4%)

477 (45.8%)

338 (37.8%)

69 (32.5%)

40 (33.9%)

 < 0.001e,f

Dosage of treatment

 Oral PSL (mg/day)

21.5 ± 19.1

19.2 ± 16.1

22.2 ± 17.9

24.0 ± 18.2

24.7 ± 17.4

0.002e,f,g

 IV mPSL (mg/day)

545.5 ± 429.4

603.3 ± 294.1

564.4 ± 266.3

526.7 ± 302.1

552.1 ± 222.7

0.282

 Cyclosporine (mg/day)

106.3 ± 45.0

95.4 ± 39.9

89.8 ± 34.9

84.4 ± 34.2

85.9 ± 30.5

 < 0.001a,b,c

 Mizoribine (mg/day)

164.3 ± 84.9

145.3 ± 50.9

135.7 ± 35.1

143.3 ± 17.6

108.3 ± 37.6

0.031

 MMF (mg/day)

1516.0 ± 472.2

906.3 ± 680.6

–

–

–

0.014

 Rituximab (mg/month)

585.4 ± 363.6

606.7 ± 456.6

630.1 ± 495.3

300.0 ± 282.8

–

0.374

Steroid‑resistant NS

25 (2.4%)

40 (3.8%)

82 (9.2%)

39 (18.4%)

27 (22.9%)

 < 0.001b,c,d,e,f,g,h

SDNS or FRNS

915 (88.2%)

803 (77.2%)

500 (55.9%)

69 (32.5%)

33 (28.0%)

 < 0.001a,b,c,d,e,f,g,h

Persistent UP ≥ 0.5 g/gCr

83 (8.0%)

154 (14.8%)

240 (26.8%)

67 (31.6%)

39 (33.1%)

 < 0.001a,b,c,e,f,g

  1. Data are expressed as median (interquartile range), mean ± SD or number (percentage).
  2. MCD minimal change disease, PSL prednisolone, mPSL methylprednisolone, MMF Mycophenolate mofetil, NS nephrotic syndrome, SDNS steroid-dependent nephrotic syndrome, FRNS frequently relapsing nephrotic syndrome.
  3. aP < 0.05, ≤ 19 y/o vs. 20–39 y/o, bP < 0.05, ≤ 19 y/o vs. 40–64 y/o, cP < 0.05, ≤ 19 y/o vs. 65–74 y/o, dP < 0.05, ≤ 19 y/o vs. ≥ 75 y/o, eP < 0.05, 20–39 y/o vs. 40–64 y/o, fP < 0.05, 20–39 y/o vs. 65–74 y/o, gP < 0.05, 20–39 y/o vs. ≥ 75 y/o, hP < 0.05, 40–64 y/o vs. 65–74 y/o, iP < 0.05, 40–64 y/o vs. ≥ 75 y/o. Kruskal–Wallis tests with Bonferroni-corrected P-values.
  4. *Number of missing values, n = 155 (14.9%) in ≤ 19 y/o; n = 98 (9.4%) in 20–39 y/o; n = 60 (6.7%) in 40–64 y/o; n = 29 (13.7%) in 65–74 y/o; n = 11 (9.3%) in ≥ 75 y/o.
Back to article page